The Rare Disease Foundation is excited to be hosting and partnering with a variety of organizations across Canada to bring Rare Disease Day events across the country. The theme of this year's International Rare Disease Day is 'Research' and we couldn't be more on board with the theme!
Thanks to Shire Canada, the Rare Disease Foundation was once again able to sponsor and support a variety of celebratory activities in multiple cities across the country. We also want to thank our National Coordinator (and volunteer) Allison Jones of North Vancouver, BC for all her assistance and commitment.
Victoria, BC - We also wish to thank the Township of Esquimalt for recognizing Rare Disease Day with an official flag raising and proclamation.
New Discovery Provides Hope for 20% of Our Community
Novel discoveries funded by the Rare Disease Foundation and recently published in the journal Nucleic Acids Research appear poised to lead to potential new therapies to treat patients across a broad array of genetic diseases.
There are over 7,000 rare genetic diseases that affect about one in twelve people or over 500 million globally. For about 20% of these people, the gene defect arises from a specific type of abnormality known as nonsense mutation; so as opposed to tackling the daunting task of developing unique therapies for each individual disease, a new therapeutic approach targeted at this mutation (and therefore multiple genetic disorders) is being developed by Dr. Michel Roberge, a Professor of Biochemistry and Molecular Biology in the University of British Columbia’s Faculty of Medicine in partnership with The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre.
Starting with a microgrant from the Rare Disease Foundation, Dr. Roberge set out to find new therapeutic solutions that are much safer for patients. His team, alongside that of CDRD, screened more than 200,000 chemical-compounds and discovered a number of novel molecules that when combined with lower, less toxic doses of aminoglycosidesenhance suppression of the premature stop signals. Subsequent modification of these compounds by CDRD’s medicinal chemistry group resulted in novel molecules that open up the possibility of treating patients across a broader spectrum of genetic diseases caused by nonsense mutations. The Rare Disease Foundation is proud to have been Dr. Roberge's first funding partner for this potentially ground-breaking research. Read more in the rotating news announcements below.